Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 909 Carboplatin 786 pembrolizumab 743 Paclitaxel 742 Cisplatin 708 Bevacizumab 706 Gemcitabine 619 Docetaxel 579 Rituximab 548 Radiotherapy 541 Dexamethasone 511 Nivolumab 488 Doxorubicin 444 Fluorouracil 392 Capecitabine 376 Etoposide 358 Pemetrexed 336 Cytarabine 335 Oxaliplatin 333 Lenalidomide 328 Prednisone 326 fludarabine phosphate 316 Erlotinib Hydrochloride 314 Trastuzumab 300 Leucovorin 299 fludarabine 296 Vincristine 287 Filgrastim 284 Bortezomib 284 Cetuximab 276

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × RAD1901 × Clear all

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡